Current drugs in systemic lupus erythematosus
Identifieur interne : 001569 ( Main/Exploration ); précédent : 001568; suivant : 001570Current drugs in systemic lupus erythematosus
Auteurs : Yiyun Yu [États-Unis, République populaire de Chine] ; Antonio La Cava [États-Unis]Source :
- Drug Development Research [ 0272-4391 ] ; 2011-11.
English descriptors
- Teeft :
- Abatacept, Abetimus, Abetimus sodium, Adverse events, Antimalarial, Ares, Aringer, Arthritis, Arthritis rheum, Azathioprine, Belimumab, Blys, Cava, Cell depletion, Cell transplantation, Clinical trial, Corticosteroid, Current drugs, Cutaneous, Cyclophosphamide, Cytokine, Cytotoxic, Diffuse proliferative lupus nephritis, Disease activity, Epratuzumab, Erythematosus, Humanized, Immunoglobulin, Immunol, Iniximab, Intravenous, Intravenous immunoglobulin, Leunomide, Lupus, Lupus erythematosus, Lupus mice, Lupus nephritis, Methotrexate, Mofetil, Monoclonal antibody, Mtor, Murine, Mycophenolate, Mycophenolate mofetil, Nephritis, Ongoing, Ongoing phase, Pathway, Peripheral blood, Pilot study, Placebo, Plasma cells, Proliferative, Proliferative lupus nephritis, Randomized, Receptor, Receptor antagonist, Refractory, Renal, Renal function, Renal involvement, Rheum, Rheumatol, Rheumatology, Rituximab, Serum levels, Side effects, Sirolimus, Small study, Systemic, Systemic lupus erythematosus, Tacrolimus, Thrombotic events, Transplantation, Wiley periodicals, Zhang.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous presentation and clinical manifestations. These aspects represent a problem in the treatment of the disease. Nonspecific medications for SLE that include antimalarials, corticosteroids, and cytotoxic drugs improve the prognosis of SLE yet carry significant side effects. Therefore, new targeted therapies that block pathways involved in the pathogenesis of SLE have been developed as possible additions to the standard management of the disease. This work reviews the current therapies and novel approaches in the treatment of SLE. Drug Dev Res 72:561–572, 2011. ©2011 Wiley Periodicals, Inc.
Url:
DOI: 10.1002/ddr.20466
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000500
- to stream Istex, to step Curation: 000500
- to stream Istex, to step Checkpoint: 000545
- to stream Main, to step Merge: 001571
- to stream Main, to step Curation: 001569
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Current drugs in systemic lupus erythematosus</title><author><name sortKey="Yu, Yiyun" sort="Yu, Yiyun" uniqKey="Yu Y" first="Yiyun" last="Yu">Yiyun Yu</name></author><author><name sortKey="La Cava, Antonio" sort="La Cava, Antonio" uniqKey="La Cava A" first="Antonio" last="La Cava">Antonio La Cava</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FD86E3C411B1C949CA442543230F437A9E55C241</idno><date when="2011" year="2011">2011</date><idno type="doi">10.1002/ddr.20466</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-PTPQ5PB2-P/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000500</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000500</idno><idno type="wicri:Area/Istex/Curation">000500</idno><idno type="wicri:Area/Istex/Checkpoint">000545</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000545</idno><idno type="wicri:doubleKey">0272-4391:2011:Yu Y:current:drugs:in</idno><idno type="wicri:Area/Main/Merge">001571</idno><idno type="wicri:Area/Main/Curation">001569</idno><idno type="wicri:Area/Main/Exploration">001569</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Current drugs in systemic lupus erythematosus</title><author><name sortKey="Yu, Yiyun" sort="Yu, Yiyun" uniqKey="Yu Y" first="Yiyun" last="Yu">Yiyun Yu</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles</wicri:cityArea></affiliation><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040</wicri:regionArea><wicri:noRegion>Shanghai 200040</wicri:noRegion></affiliation></author><author><name sortKey="La Cava, Antonio" sort="La Cava, Antonio" uniqKey="La Cava A" first="Antonio" last="La Cava">Antonio La Cava</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles</wicri:cityArea></affiliation><affiliation wicri:level="1"><country wicri:rule="url">États-Unis</country></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Californie</region></placeName><wicri:cityArea>Correspondence address: Division of Rheumatology, David Geffen School of Medicine, University of California Los Angeles, 1000 Veteran Avenue 32‐59, Los Angeles</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Drug Development Research</title><title level="j" type="sub">Special Issue: Drugs for Autoimmune Disorders: Part I</title><title level="j" type="alt">DRUG DEVELOPMENT RESEARCH</title><idno type="ISSN">0272-4391</idno><idno type="eISSN">1098-2299</idno><imprint><biblScope unit="vol">72</biblScope><biblScope unit="issue">7</biblScope><biblScope unit="page" from="561">561</biblScope><biblScope unit="page" to="572">572</biblScope><biblScope unit="page-count">12</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2011-11">2011-11</date></imprint><idno type="ISSN">0272-4391</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0272-4391</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Abatacept</term><term>Abetimus</term><term>Abetimus sodium</term><term>Adverse events</term><term>Antimalarial</term><term>Ares</term><term>Aringer</term><term>Arthritis</term><term>Arthritis rheum</term><term>Azathioprine</term><term>Belimumab</term><term>Blys</term><term>Cava</term><term>Cell depletion</term><term>Cell transplantation</term><term>Clinical trial</term><term>Corticosteroid</term><term>Current drugs</term><term>Cutaneous</term><term>Cyclophosphamide</term><term>Cytokine</term><term>Cytotoxic</term><term>Diffuse proliferative lupus nephritis</term><term>Disease activity</term><term>Epratuzumab</term><term>Erythematosus</term><term>Humanized</term><term>Immunoglobulin</term><term>Immunol</term><term>Iniximab</term><term>Intravenous</term><term>Intravenous immunoglobulin</term><term>Leunomide</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus mice</term><term>Lupus nephritis</term><term>Methotrexate</term><term>Mofetil</term><term>Monoclonal antibody</term><term>Mtor</term><term>Murine</term><term>Mycophenolate</term><term>Mycophenolate mofetil</term><term>Nephritis</term><term>Ongoing</term><term>Ongoing phase</term><term>Pathway</term><term>Peripheral blood</term><term>Pilot study</term><term>Placebo</term><term>Plasma cells</term><term>Proliferative</term><term>Proliferative lupus nephritis</term><term>Randomized</term><term>Receptor</term><term>Receptor antagonist</term><term>Refractory</term><term>Renal</term><term>Renal function</term><term>Renal involvement</term><term>Rheum</term><term>Rheumatol</term><term>Rheumatology</term><term>Rituximab</term><term>Serum levels</term><term>Side effects</term><term>Sirolimus</term><term>Small study</term><term>Systemic</term><term>Systemic lupus erythematosus</term><term>Tacrolimus</term><term>Thrombotic events</term><term>Transplantation</term><term>Wiley periodicals</term><term>Zhang</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous presentation and clinical manifestations. These aspects represent a problem in the treatment of the disease. Nonspecific medications for SLE that include antimalarials, corticosteroids, and cytotoxic drugs improve the prognosis of SLE yet carry significant side effects. Therefore, new targeted therapies that block pathways involved in the pathogenesis of SLE have been developed as possible additions to the standard management of the disease. This work reviews the current therapies and novel approaches in the treatment of SLE. Drug Dev Res 72:561–572, 2011. ©2011 Wiley Periodicals, Inc.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="États-Unis"><region name="Californie"><name sortKey="Yu, Yiyun" sort="Yu, Yiyun" uniqKey="Yu Y" first="Yiyun" last="Yu">Yiyun Yu</name></region><name sortKey="La Cava, Antonio" sort="La Cava, Antonio" uniqKey="La Cava A" first="Antonio" last="La Cava">Antonio La Cava</name><name sortKey="La Cava, Antonio" sort="La Cava, Antonio" uniqKey="La Cava A" first="Antonio" last="La Cava">Antonio La Cava</name><name sortKey="La Cava, Antonio" sort="La Cava, Antonio" uniqKey="La Cava A" first="Antonio" last="La Cava">Antonio La Cava</name></country><country name="République populaire de Chine"><noRegion><name sortKey="Yu, Yiyun" sort="Yu, Yiyun" uniqKey="Yu Y" first="Yiyun" last="Yu">Yiyun Yu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001569 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001569 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FD86E3C411B1C949CA442543230F437A9E55C241
|texte= Current drugs in systemic lupus erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |